Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Keratosis, Actinic 12Pain 3Breast Neoplasms 3Pain, Postoperative 2Non-melanoma Skin Cancer 2Lymphoma, Follicular 2Lung Neoplasms 2Acute Pain 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Respiratory Aspiration 1Prostatic Hyperplasia 1Pneumothorax 1Pleural Neoplasms 1Pleural Effusion 1Photosensitivity Disorders 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lower Urinary Tract Symptoms 1Hematuria 1Hand-Foot Syndrome 1Empyema, Pleural 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Diclofenac × Clear all
NCT01596647 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡